Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nathan Erdmann
University of Alabama at Birmingham
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alabama Crs
Birmingham, Alabama, United States
- Brigham and Women'S Hospital Vaccine Crs (bwh Vcrs)
Boston, Massachusetts, United States
- Fenway Health (fh) Crs
Boston, Massachusetts, United States
- Columbia P&s Crs
New York, New York, United States
- New York Blood Center Crs
New York, New York, United States
- Seattle Vaccine and Prevention Crs
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Aug 2019
- Primary completion
- 5 Feb 2021
- Completion
- 26 May 2021
- Last update posted
- 25 Sept 2025
- Registered enrollment
- 24
- Registry id
- NCT03934541
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.